Pfizer Inc.
NYSE:PFE 3:37:21 PM EDT
Products, Regulatory
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody in Multiple Myeloma
Published: 12/07/2020 12:21 GMT
Pfizer Inc. (PFE) - Pfizer Reports Positive Clinical Data for Bcma-cd3 Bispecific Antibody (pf-06863135) in Multiple Myeloma.
Pfizer Inc - Data From 30 Patients With Relapsed Or Refractory Multiple Myeloma Showed Manageable Safety Across All Subcutaneous Dose Levels.
Pfizer Inc - Phase 1 Study Showed No Dose-limiting Toxicities Observed, 83% of Patients Achieved a Clinical Response at Highest Dose Level.
Pfizer Inc - Data From 30 Patients With Relapsed Or Refractory Multiple Myeloma Showed Manageable Safety Across All Subcutaneous Dose Levels.
Pfizer Inc - Phase 1 Study Showed No Dose-limiting Toxicities Observed, 83% of Patients Achieved a Clinical Response at Highest Dose Level.